Prithvi Arunachalam
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Prithvi Arunachalam has a total of 109 co-authors. Here are the top co-authors by number of shared publications:
- Alle Meije Wink
Department of Radiology and Nuclear Medicine, Vrije Universiteit Amsterdam, Amsterdam UMC, location VUmc, the Netherlands
3 shared publications - Frederik Barkhof
Amsterdam UMC, Location VUmc
3 shared publications - Leonard Pieperhoff
Amsterdam UMC, Amsterdam Netherlands
3 shared publications - Luigi Lorenzini
Department of Radiology and Nuclear Medicine Amsterdam University Medical Centre, Vrije Universiteit Amsterdam The Netherlands
3 shared publications - Lyduine E. Collij
Department of Radiology and Nuclear Medicine, UMC Vrije Universiteit Amsterdam, Amsterdam, The Netherlands
3 shared publications - Michael Schöll
Wallenberg Centre for Molecular and Translational Medicine, University of Gothenburg, Gothenburg, Sweden
3 shared publications
Latest Publications
- Open Access
Normative Modeling of Molecular-Enriched Functional Connectivity for Detecting Deviations from Healthy Brain Aging
Introduction: Inter-individual variability in adult brain aging can obscure early pathological alterations and is only partly represented by population-average or scalar brain-aging measures. We combined Receptor-Enriched Analysis of functional Connectivity by Targets (REACT) with normative modeling (NM) to derive spatially resolved, molecularly informed deviation scores for dopamine transporter (DAT)-, norepinephrine transporter (NET)-, and serotonin transporter (SERT)-enriched resting-state functional connectivity (FC). We first evaluated whether these normative models could be transferred to independently processed external data through local calibration and then explored whether the resulting deviation profiles differed with cerebral amyloid burden in cognitively unimpaired older adults. Methods: Hierarchical Bayesian regression (HBR) models with a sinh–arcsinh likelihood (SHASHb) were estimated separately for 204 cortical molecular-enriched FC features in 4,152 healthy adults (18.0–89.8 years) from seven publicly available neuroimaging datasets and evaluated in a held-out healthy test set. Pretrained models were locally adapted to three Amyloid Imaging to Prevent Alzheimer’s Disease Prognostic and Natural History Study (AMYPAD-PNHS) acquisition batches using cognitively unimpaired, amyloid-negative participants (global Clinical Dementia Rating (CDR) = 0; Centiloid (CL) < 10). The independent primary comparison contrasted participants with intermediate amyloid burden (10 ≤ CL < 30; n = 111) and amyloid-positive participants (CL ≥ 30; n = 66); secondary analyses tested linear associations with continuous CL within participants with CL ≥ 10. Results: Of 204 normative reference models, 199 (97.5%) met the predefined diagnostic criteria; median held-out explained variance (EXPV) was 0.174. Of 612 feature-by-batch transfers, 541 (88.4%) met the strict transfer-diagnostic criteria. In the primary false discovery rate (FDR)-controlled regional analysis, DAT-enriched right caudal middle frontal cortex showed lower locally standardized deviation scores in the intermediate-amyloid-burden group than in the amyloid-positive group (adjusted difference = −0.582, q = 0.016). DAT extreme-deviation burden was also greater in the intermediate-amyloid-burden group (difference = 0.032, q = 0.044). The right frontal effect was reproduced with model-native scores across the three acquisition batches (pooled standardized effect = −0.698, q = 0.010). No NET- or SERT-enriched regional difference between these two groups survived FDR-correction, and no regional or subject-level linear association with continuous CL values survived FDR-correction in the CL ≥ 10 group. Conclusion: NM can provide spatially resolved reference distributions of molecular-enriched FC that are deployable in independently processed external data when local adaptation, calibration, and feature-level transfer diagnostics are incorporated. The AMYPAD-PNHS application identified modest, spatially selective, and molecular-system-specific categorical differences during a cognitively unimpaired stage of amyloid accumulation, while continuous analyses within CL ≥ 10 did not support linear association. These findings support a methodological basis for distributed application of molecular-enriched normative models and motivate independent and longitudinal evaluation of their biological relevance. Key Points: Hierarchical normative models characterized 204 regional DAT-, NET-, and SERT-enriched FC features across 4,152 healthy adults; 199/204 models met the predefined normative-reference-model diagnostic criteria. Local hierarchical adaptation enabled the pretrained normative models to be applied to independently processed AMYPAD-PNHS data without centralized reprocessing of the target raw images or explicit feature-level harmonization; 541/612 feature–batch transfers met the strict transfer criteria. In cognitively unimpaired AMYPAD-PNHS participants, the exploratory amyloid application identified a spatially selective DAT-enriched right frontal difference and greater DAT extreme-deviation burden in the intermediate-amyloid-burden group than in the amyloid-positive group. No FDR-corrected regional NET or SERT differences between these groups and no FDR-corrected linear associations with continuous CL were identified.
Open AccessNormative Modeling of Molecular-Enriched Functional Connectivity for Detecting Deviations from Healthy Brain Aging
Introduction: Inter-individual variability in adult brain aging can obscure early pathological alterations and is only partly represented by population-average or scalar brain-aging measures. We combined Receptor-Enriched Analysis of functional Connectivity by Targets (REACT) with normative modeling (NM) to derive spatially resolved, molecularly informed deviation scores for dopamine transporter (DAT)-, norepinephrine transporter (NET)-, and serotonin transporter (SERT)-enriched resting-state functional connectivity (FC). We first evaluated whether these normative models could be transferred to independently processed external data through local calibration and then explored whether the resulting deviation profiles differed with cerebral amyloid burden in cognitively unimpaired older adults. Methods: Hierarchical Bayesian regression (HBR) models with a sinh–arcsinh likelihood (SHASHb) were estimated separately for 204 cortical molecular-enriched FC features in 4,152 healthy adults (18.0–89.8 years) from seven publicly available neuroimaging datasets and evaluated in a held-out healthy test set. Pretrained models were locally adapted to three Amyloid Imaging to Prevent Alzheimer’s Disease Prognostic and Natural History Study (AMYPAD-PNHS) acquisition batches using cognitively unimpaired, amyloid-negative participants (global Clinical Dementia Rating (CDR) = 0; Centiloid (CL) < 10). The independent primary comparison contrasted participants with intermediate amyloid burden (10 ≤ CL < 30; n = 111) and amyloid-positive participants (CL ≥ 30; n = 66); secondary analyses tested linear associations with continuous CL within participants with CL ≥ 10. Results: Of 204 normative reference models, 199 (97.5%) met the predefined diagnostic criteria; median held-out explained variance (EXPV) was 0.174. Of 612 feature-by-batch transfers, 541 (88.4%) met the strict transfer-diagnostic criteria. In the primary false discovery rate (FDR)-controlled regional analysis, DAT-enriched right caudal middle frontal cortex showed lower locally standardized deviation scores in the intermediate-amyloid-burden group than in the amyloid-positive group (adjusted difference = −0.582, q = 0.016). DAT extreme-deviation burden was also greater in the intermediate-amyloid-burden group (difference = 0.032, q = 0.044). The right frontal effect was reproduced with model-native scores across the three acquisition batches (pooled standardized effect = −0.698, q = 0.010). No NET- or SERT-enriched regional difference between these two groups survived FDR-correction, and no regional or subject-level linear association with continuous CL values survived FDR-correction in the CL ≥ 10 group. Conclusion: NM can provide spatially resolved reference distributions of molecular-enriched FC that are deployable in independently processed external data when local adaptation, calibration, and feature-level transfer diagnostics are incorporated. The AMYPAD-PNHS application identified modest, spatially selective, and molecular-system-specific categorical differences during a cognitively unimpaired stage of amyloid accumulation, while continuous analyses within CL ≥ 10 did not support linear association. These findings support a methodological basis for distributed application of molecular-enriched normative models and motivate independent and longitudinal evaluation of their biological relevance. Key Points: Hierarchical normative models characterized 204 regional DAT-, NET-, and SERT-enriched FC features across 4,152 healthy adults; 199/204 models met the predefined normative-reference-model diagnostic criteria. Local hierarchical adaptation enabled the pretrained normative models to be applied to independently processed AMYPAD-PNHS data without centralized reprocessing of the target raw images or explicit feature-level harmonization; 541/612 feature–batch transfers met the strict transfer criteria. In cognitively unimpaired AMYPAD-PNHS participants, the exploratory amyloid application identified a spatially selective DAT-enriched right frontal difference and greater DAT extreme-deviation burden in the intermediate-amyloid-burden group than in the amyloid-positive group. No FDR-corrected regional NET or SERT differences between these groups and no FDR-corrected linear associations with continuous CL were identified.
- Open Access
- 23 June 2026
- Published by Wiley in Alzheimer's & Dementia
- Vol. 22 (6) , e71609
Cortical gray–white matter contrast alterations precede amyloid‐β positivity and macrostructural changes in older adults without dementia
INTRODUCTION: Early Alzheimer's disease (AD) involves subtle cortical changes that may precede atrophy. Magnetic resonance imaging (MRI) microstructural markers may detect earlier pathology than classical morphometry. METHODS: We analyzed cross‐sectional MRI and amyloid‐β (Aβ) positron emission tomography (PET) data from 1323 non‐demented AMYPAD participants. Cortical volume, thickness, gray–white matter contrast (GWC), and mean diffusivity (MD) were related to global Aβ burden and estimated time to Aβ‐positivity using regression, correlation, and change‐point analyses. RESULTS: Microstructural measures showed stronger age associations than macrostructural measures, whereas all measures were unaffected by apolipoprotein E ( APOE) ‐ε4 carriership. GWC and MD showed minimal overlap with volume and thickness. Higher Aβ burden was most strongly associated with reduced GWC and cortical thinning. Change‐point analyses showed GWC alterations preceded Aβ‐positivity by several years. DISCUSSION: Cortical microstructural MRI, particularly GWC, changes earlier than atrophy and may serve as an early in vivo marker of AD pathology.
- 23 June 2026
- Published by Wiley in Alzheimer's & Dementia
- Vol. 22 (6) , e71609
Open AccessCortical gray–white matter contrast alterations precede amyloid‐β positivity and macrostructural changes in older adults without dementia
INTRODUCTION: Early Alzheimer's disease (AD) involves subtle cortical changes that may precede atrophy. Magnetic resonance imaging (MRI) microstructural markers may detect earlier pathology than classical morphometry. METHODS: We analyzed cross‐sectional MRI and amyloid‐β (Aβ) positron emission tomography (PET) data from 1323 non‐demented AMYPAD participants. Cortical volume, thickness, gray–white matter contrast (GWC), and mean diffusivity (MD) were related to global Aβ burden and estimated time to Aβ‐positivity using regression, correlation, and change‐point analyses. RESULTS: Microstructural measures showed stronger age associations than macrostructural measures, whereas all measures were unaffected by apolipoprotein E ( APOE) ‐ε4 carriership. GWC and MD showed minimal overlap with volume and thickness. Higher Aβ burden was most strongly associated with reduced GWC and cortical thinning. Change‐point analyses showed GWC alterations preceded Aβ‐positivity by several years. DISCUSSION: Cortical microstructural MRI, particularly GWC, changes earlier than atrophy and may serve as an early in vivo marker of AD pathology.
- Open Access
- 9 June 2026
- Published by Springer Nature in Communications Medicine
- Vol. 6 (1)
Decreased amyloid-related structure–function coupling in preclinical Alzheimer’s disease
Structural pathways of the brain facilitate functional communication, and their disruption in preclinical Alzheimer's disease may reflect network vulnerability and compensatory brain maintenance. However, it remains unclear how early amyloid-β affects structure-function alignment, whether effects are explained by functional network organisation, how they relate to cognition, and which biological processes contribute to their development. We included 460 older adults without dementia from AMYPAD-PNHS with functional MRI, diffusion MRI, and amyloid-β PET. Structure-function coupling was quantified using the structural-decoupling index (SDI) at global, sub-network, and regional scales. Linear models investigated the effect of amyloid-β burden on SDI. Mediation analyses evaluated whether functional graph topology explained amyloid-associated SDI effects and whether SDI mediated the relationship between amyloid-β burden and cognition. Regional gene expression data were integrated to assess transcriptomic determinants of amyloid-related structure-function coupling. Amyloid-positive individuals exhibit higher global SDI, driven by visual cortices. Mediation analyses demonstrate that amyloid-related SDI alterations are explained by reductions in local clustering, indicating less segregated processing. Despite higher SDI in amyloid-positive individuals, elevated SDI in visual regions mitigates the negative effect of amyloid-β burden on cognition. Amyloid-related SDI changes correlate with genes associated with amyloid-β metabolism, microglial activation, and synaptic remodelling. Early amyloid-β pathology is associated with decoupling of brain structure and function, primarily in visual cortices, mediated by network reconfiguration and shaped by regional molecular architecture. These findings suggest that lower structure-function coupling may represent a compensatory mechanism in preclinical Alzheimer's disease and highlight SDI as a biomarker for stratification and monitoring in prevention trials.
- 9 June 2026
- Published by Springer Nature in Communications Medicine
- Vol. 6 (1)
Open AccessDecreased amyloid-related structure–function coupling in preclinical Alzheimer’s disease
Structural pathways of the brain facilitate functional communication, and their disruption in preclinical Alzheimer's disease may reflect network vulnerability and compensatory brain maintenance. However, it remains unclear how early amyloid-β affects structure-function alignment, whether effects are explained by functional network organisation, how they relate to cognition, and which biological processes contribute to their development. We included 460 older adults without dementia from AMYPAD-PNHS with functional MRI, diffusion MRI, and amyloid-β PET. Structure-function coupling was quantified using the structural-decoupling index (SDI) at global, sub-network, and regional scales. Linear models investigated the effect of amyloid-β burden on SDI. Mediation analyses evaluated whether functional graph topology explained amyloid-associated SDI effects and whether SDI mediated the relationship between amyloid-β burden and cognition. Regional gene expression data were integrated to assess transcriptomic determinants of amyloid-related structure-function coupling. Amyloid-positive individuals exhibit higher global SDI, driven by visual cortices. Mediation analyses demonstrate that amyloid-related SDI alterations are explained by reductions in local clustering, indicating less segregated processing. Despite higher SDI in amyloid-positive individuals, elevated SDI in visual regions mitigates the negative effect of amyloid-β burden on cognition. Amyloid-related SDI changes correlate with genes associated with amyloid-β metabolism, microglial activation, and synaptic remodelling. Early amyloid-β pathology is associated with decoupling of brain structure and function, primarily in visual cortices, mediated by network reconfiguration and shaped by regional molecular architecture. These findings suggest that lower structure-function coupling may represent a compensatory mechanism in preclinical Alzheimer's disease and highlight SDI as a biomarker for stratification and monitoring in prevention trials.
- Open Access
- 9 January 2026
- Published by Springer Nature in Alzheimer's Research & Therapy
- Vol. 18 (1)
Clinical translation of fluid, imaging, and digital biomarkers for Alzheimer’s disease
Alzheimer’s disease (AD) is the most common neurodegenerative disorder, affecting millions worldwide. The clinical presentation of AD is heterogenous
- 9 January 2026
- Published by Springer Nature in Alzheimer's Research & Therapy
- Vol. 18 (1)
Open AccessClinical translation of fluid, imaging, and digital biomarkers for Alzheimer’s disease
Alzheimer’s disease (AD) is the most common neurodegenerative disorder, affecting millions worldwide. The clinical presentation of AD is heterogenous
- Open Access
- 4 December 2025
- Published by Springer Nature in Alzheimer's Research & Therapy
- Vol. 18 (1)
Longitudinal biomarker studies in human neuroimaging: capturing biological change of Alzheimer’s pathology
Despite extensive research, open questions about the biological underpinnings of Alzheimer’s disease (AD) remain. Neuroimaging biomarkers based on positron emission tomography (PET) and magnetic resonance imaging (MRI) offer in vivo insights into these complex biological changes and interactions. However, most evidence to date comes from cross-sectional studies, limiting our understanding of disease progression. Longitudinal studies enable the investigation of biological changes within individuals, revealing how pathology evolves over time. With this review, we provide an overview of how longitudinal imaging biomarker studies have advanced the field and how they can contribute to future research. We highlight longitudinal biomarker studies that have provided critical insights into disease trajectories, staging, and individual variability. We further assess longitudinal multimodal studies which have elucidated interactions between AD-specific pathology, amyloid-β and tau, and broader biological changes like neurodegeneration, neuronal dysfunction, vascular disease, and inflammation. Further, we discuss associations of brain changes with symptomatology and clinical outcomes and conclude with challenges and future directions.
- 4 December 2025
- Published by Springer Nature in Alzheimer's Research & Therapy
- Vol. 18 (1)
Open AccessLongitudinal biomarker studies in human neuroimaging: capturing biological change of Alzheimer’s pathology
Despite extensive research, open questions about the biological underpinnings of Alzheimer’s disease (AD) remain. Neuroimaging biomarkers based on positron emission tomography (PET) and magnetic resonance imaging (MRI) offer in vivo insights into these complex biological changes and interactions. However, most evidence to date comes from cross-sectional studies, limiting our understanding of disease progression. Longitudinal studies enable the investigation of biological changes within individuals, revealing how pathology evolves over time. With this review, we provide an overview of how longitudinal imaging biomarker studies have advanced the field and how they can contribute to future research. We highlight longitudinal biomarker studies that have provided critical insights into disease trajectories, staging, and individual variability. We further assess longitudinal multimodal studies which have elucidated interactions between AD-specific pathology, amyloid-β and tau, and broader biological changes like neurodegeneration, neuronal dysfunction, vascular disease, and inflammation. Further, we discuss associations of brain changes with symptomatology and clinical outcomes and conclude with challenges and future directions.